Clinical Trials Related to Acute Myeloid Leukemia

Related studies linked through entity extraction aliases.

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Status: RECRUITING
Phase: PHASE1

Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

Status: RECRUITING
Phase: PHASE2

Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients

Status: WITHDRAWN
Phase: PHASE2

Venetoclax in Combination With Standard Induction and Consolidation Chemotherapy in Newly Diagnosed Young AML Patients

Status: ENROLLING_BY_INVITATION
Phase: N/A

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

Status: RECRUITING
Phase: PHASE1/PHASE2

Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

Status: TERMINATED
Phase: PHASE1

CIML NK Cells With Venetoclax for AML

Status: RECRUITING
Phase: PHASE1

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

Status: RECRUITING
Phase: PHASE1

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

Status: RECRUITING
Phase: PHASE1

Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML

Status: NOT_YET_RECRUITING
Phase: PHASE2

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

Status: RECRUITING
Phase: PHASE1/PHASE2

Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Status: RECRUITING
Phase: PHASE2

A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia

Status: WITHDRAWN
Phase: PHASE1/PHASE2

Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement

Status: RECRUITING
Phase: N/A

Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML

Status: TERMINATED
Phase: EARLY_PHASE1

A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid Leukemia

Status: RECRUITING
Phase: N/A

Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients

Status: NOT_YET_RECRUITING
Phase: PHASE3

Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Status: TERMINATED
Phase: PHASE1

Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia

Status: COMPLETED
Phase: PHASE2

Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy

Status: ACTIVE_NOT_RECRUITING
Phase: NA